当前位置：   首页 > 需求大厅

日本住友药业的注射用美罗培南说明书，要CFDA今年批准修订的最新版本的。   [更多]

具体要求：1.必须过了GMP认证 2.需要小水针 3.在北京市范围之内的厂家。   [更多]

具体需要：提供盐酸多巴胺的复核说明、检验报告。 1.提供的复核说明、检验报告真实有效，核实后付款。 2.必须为现行的复核说明、检验报告。 3.价格可议 有意者请与我联系   [更多]

在合理合法的范围内   [更多]

详细要求：1、批文的格式为：X药制字H(Z)+4位年号+4位流水号；其中，X表示省、自治区、直辖市简称，H表示化学制剂，Z表示中药制剂） 2、最好是生化药或植物药 3、要求直接提供转让单位的名称和联系方式。   [更多]

我公司有强大的研发实力，现有注射用头孢曲松钠、注射用头孢他啶、注射用头孢噻肟钠、注射用舒巴坦钠、灭菌注射用水等项目可转临床批文，现需找寻优质客户。   [更多]

成本，生产周期，产品质量，工艺规模请列出。   [更多]

设备应能至少每分钟测量血含量两次，连续测量时间至少60分钟。探头小巧并方便弯曲，准确度：设备必须能够衡量的范围为0 - 1.25毫升的血（稀释在大约15 - 30毫升的盐水中），精度要测准大约6µl的血（稀释在大约15 - 30毫升的盐水中）。 具体如下：https://www.innocentive.com/ar/challenge/9933690 The Seeker desires a device to continuously and/or repeatedly measure the amount of blood in a volume of saline. The device should be capable of measuring at least twice per minute for at least 60 minutes. This is a Reduction-to-Practice Challenge that requires a written proposal, experimental proof-of-concept data, and prototype delivery if requested Source: InnoCentive Challenge ID: 9933690 Challenge Overview The Seeker is looking for a device to continuously measure blood content in a small volume of saline. Blood is introduced continuously through a thin, flexible probe placed in the container of saline and the device must be able to measure the overall blood content in the container at least twice per minute for at least 60 minutes. The device must be able to measure over the range of 0 – 1.25 ml of blood in approximately 15 – 30 ml of saline with an accuracy of approximately 6 µl of blood. Only minimal stirring is allowed, thus devices should not rely on an assumption of uniform mixing of the blood in the saline solution. The rate of blood introduction may vary significantly, and may start and stop numerous times. The submission to the Challenge should include the following: The detailed description of the proposed Solution addressing specific Solution Requirements presented in the Detailed Description of the Challenge. This description should be accompanied by a well-articulated rationale supported by literature/patent precedents. Experimental proof-of-concept data obtained as outlined in the Detailed Description of the Challenge (and delivery of a prototype if requested by the Seeker).   [更多]

罕见癌症研究基金会(RCRF),致力于通过战略投资和创新合作进行基础治疗罕见的癌症,和美国文化募捐组织(ATCC),世界上最大的非营利性细胞株库,建立神经内分泌肿瘤细胞株收集目录。肠道良性肿瘤和胰腺神经内分泌肿瘤(PNET)需求一种新疗法的研究和发展，即在体内原发性肿瘤中建立新的细胞株。 为了刺激发展新的良性肿瘤和PNET细胞系,该基金会是高兴地宣布第二次开放竞争十个人奖项:开发人员的第一个新的细胞系在每个疾病(肠道良性肿瘤和PNET)将获得100000美元，开发者的第二,第三,第四,第五个新细胞系在每个疾病将会收到50000美元。原文如下：https://www.innocentive.com/ar/challenge/9933756 The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Caring for Carcinoid Foundation therefore wishes to launch a second Challenge to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog. This is a Reduction-to-Practice Challenge that requires written documentation, detailed description of each cell line, and sample delivery. Source: InnoCentive Challenge ID: 9933756 Challenge Overview This Challenge is intended to encourage innovative approaches to establishing new cell lines from primary tumors that grow slowly in vivo and to publicize new methods as well as availability of the new cell lines for broad, unrestricted use. To stimulate development of new carcinoid and PNET cell lines, the Foundation is pleased to announce its second open competition for up to ten individual prizes: Developers of the first new cell lines in each disease (intestinal carcinoid and PNET) will receive $100,000 each and developers of the second, third, fourth, and fifth new cell lines in each disease will receive $50,000 each. Individual   [更多]

1,简介,ＸＸＸ制药有限公司于2006年取得药品、卫生健康产品生产许可证、注册资本1000万元。Ｘ乂Ｘ制药是研究开发、生产、销售外用治疗药品、大健康产业的对环境空气、物质、预防消毒产品、功能性健康产品、功能性药妆和日化产品、功能性家庭日用健康品的专业基地。剂型分别是栓剂、乳膏剂、软膏剂、凝胶剂、乳霜、乳液、液体剂、洗液、胶囊剂、医疗器械。长期与沈阳药科大学、同济医学院、中南民族大学、武汉大学生命学院合作研究开发产品，并连续三年获得科学进步奖和科学技术创新基金。2009年公司一次性整体通过国家药品GMP认证，致力于做中国大健康产业“健康外用产品”专业生产经营企业。 2,要求,股权转让 3,时间,2015年9月30日前 4,交稿方式：直接点击交稿在线交稿就是了，我会每天过来看的，谢谢各位药智的战友们   [更多]